Mounjaro and Liver Damage: What the Evidence Shows

What clinical trial data found — and what it did not

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed 2,539 adults over 72 weeks. Liver enzyme levels were among the safety markers tracked throughout. Researchers did not identify a hepatotoxic signal, that is, there was no pattern of liver injury attributable to tirzepatide. Average body-weight fell by around 20–21% at the 15 mg dose, and reductions of that scale are consistently associated with improvements in liver fat in people with metabolic-associated steatotic liver disease (MASLD, previously called NAFLD). Tirzepatide's specific effects on liver fat are an active area of research, with early dedicated studies showing promising reductions in hepatic steatosis, though this is not a licensed indication, and treatment decisions are made on the basis of licensed use. The broader picture of how Mounjaro interacts with liver function draws on this same body of evidence. The honest summary is that, in the trials conducted so far, the medicine did not damage the liver and may have helped it in people who carry significant liver fat at baseline.

A common worry, and why it persists

A lot of people searching this topic are anxious that a powerful weight-loss medicine must, at some level, be hard on the liver. It is a reasonable instinct: many medicines are processed hepatically, and some carry genuine liver-toxicity warnings. Tirzepatide does not carry one, and there is no mechanistic reason to expect it to cause liver injury. The GIP and GLP-1 receptors it acts on are primarily involved in appetite, satiety and insulin signalling; the liver is not where the medicine does its main work. That worry, understandable as it is, does not match what the data show. What the data do show is a recognised, infrequent risk of pancreatitis (inflammation of the pancreas, not the liver) which the MHRA highlighted in a formal Drug Safety Update in January 2026. The symptom to act on is severe stomach pain that does not pass and radiates toward the back, with or without vomiting: that needs urgent medical attention. You can read a detailed look at whether Mounjaro can cause liver damage for a fuller breakdown of the distinction.

Pre-existing liver conditions and what prescribers consider

If you already have a diagnosed liver condition, the picture requires more care. Severe hepatic impairment was an exclusion criterion in the main tirzepatide trials, so robust safety data in that group is limited. Mild-to-moderate liver disease is not an absolute contraindication listed in the Summary of Product Characteristics, but it is exactly the kind of factor that a prescriber needs to know about before recommending treatment. The clinical review at a regulated UK pharmacy covers this, our clinical team reads your full medical history, not just your BMI. People with alcohol-related liver disease should also be aware that alcohol interacts with the treatment in other ways; the evidence on drinking whilst on Mounjaro is worth reading separately. And since the kidneys are involved in clearing some of the effects of GI side effects (dehydration from nausea and vomiting can stress renal function), kidney health is a related consideration that the same prescriber review covers. If you have concerns about fluid intake on treatment, staying hydrated on Mounjaro is a practical area our team fields questions on regularly.

Who to speak to and what to do next

If you have no known liver condition and are considering treatment for weight management, the evidence available gives no specific cause for concern about liver damage from tirzepatide. The MHRA-approved prescribing information, available through the electronic Medicines Compendium (eMC), lists known risks clearly and liver toxicity is not among them. If you have an existing liver diagnosis, bring your records or a GP summary to the consultation: a prescriber will weigh the benefit-to-risk balance for your specific situation and may recommend a conversation with your hepatologist first. Pregnancy, breastfeeding and trying to conceive are all situations in which Mounjaro is not recommended, regardless of liver health, and that guidance applies without exception. Tirzepatide is not licensed for under-18s. For the broader context on the treatment itself, the Mounjaro overview page covers eligibility, the licensed schedule and how private access works in the UK. If cost is part of the decision, the cost context page explains what UK private treatment typically involves. When you are ready to take the next step, you can check your eligibility with our prescribers through a free consultation.